We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 13.00 | 0.79% | 1,649.00 | 1,648.50 | 1,649.00 | 1,655.00 | 1,635.00 | 1,642.00 | 716,778 | 09:59:51 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.71 | 67.54B |
From Apr 2019 to Apr 2024
By Sabela Ojea
GlaxoSmithKline PLC said Thursday that it has started the Phase 2/3 clinical trials of its plant-derived vaccine candidate against Covid-19, adding that Phase 3 will enroll over 30,000 volunteers world-wide.
The British pharmaceutical giant said the current phase of the trial, being developed in collaboration with Medicago--a biopharmaceutical company--will evaluate the efficacy, immunogenicity, and safety of the vaccine candidate.
"Based on the positive Phase 1 results, Medicago has decided to launch the Phase 2/3 clinical trial with GSK's pandemic adjuvant," GSK said.
Shares at 1309 GMT were up 0.20 pence, or 0.01%, at 1,444.60 pence.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
November 12, 2020 08:34 ET (13:34 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
